Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas J Watson

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Pharmacoepidemiology and Drug Safety|November 7, 2006
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort studyElham Rahme, Douglas J Watson, Sheldon X Kong, et al.
Current Medical Research and Opinion|May 20, 2008
Dosage, titration, and gaps in treatment with extended release niacin in clinical practiceSachin J Kamal-Bahl, Thomas A Burke, Douglas J Watson, et al.
Pharmacoepidemiology and Drug Safety|January 5, 2006
Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medicationsPriscilla Velentgas, William West, Carolyn C Cannuscio, et al.
Managed Care Interface|September 3, 2004
Utilization patterns of cyclooxygenase-2 inhibitors among patients with arthritis in a managed care settingKathleen A Foley, Suna Barlas, Jennifer Hinnethal, et al.
International Journal of Inflammation|July 15, 2011
Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scaleMelissa E Stauffer, Stephanie D Taylor, Douglas J Watson, et al.
Clinical Therapeutics|September 21, 2002
Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature reviewPaul Emery, Sheldon X Kong, Elliot W Ehrich, et al.
American Journal of Hematology|October 7, 2017
Impact of screening and exclusion of high anti-A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital-based cohort study in the USCarlos Martinez, Douglas J Watson, Amgad Shebl, et al.
Pharmacoepidemiology and Drug Safety|June 19, 2003
Liver function testing in patients on HMG-CoA reductase inhibitorsSusan E Andrade, James G Donahue, K Arnold Chan, et al.
Current Medical Research and Opinion|October 7, 2004
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysisDouglas J Watson, Qinfen Yu, James A Bolognese, et al.
Open Access Rheumatology : Research and Reviews|July 29, 2013
A measure of treatment response: patient and physician satisfaction with traditional NSAIDs for osteoarthritis controlStephanie D Taylor, Sharlette V Everett, Thomas N Taylor, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Pharmacoepidemiology and Drug Safety|November 7, 2006
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort studyElham Rahme, Douglas J Watson, Sheldon X Kong, et al.
Current Medical Research and Opinion|May 20, 2008
Dosage, titration, and gaps in treatment with extended release niacin in clinical practiceSachin J Kamal-Bahl, Thomas A Burke, Douglas J Watson, et al.
Pharmacoepidemiology and Drug Safety|January 5, 2006
Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medicationsPriscilla Velentgas, William West, Carolyn C Cannuscio, et al.
Managed Care Interface|September 3, 2004
Utilization patterns of cyclooxygenase-2 inhibitors among patients with arthritis in a managed care settingKathleen A Foley, Suna Barlas, Jennifer Hinnethal, et al.
International Journal of Inflammation|July 15, 2011
Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scaleMelissa E Stauffer, Stephanie D Taylor, Douglas J Watson, et al.
Clinical Therapeutics|September 21, 2002
Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature reviewPaul Emery, Sheldon X Kong, Elliot W Ehrich, et al.
American Journal of Hematology|October 7, 2017
Impact of screening and exclusion of high anti-A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital-based cohort study in the USCarlos Martinez, Douglas J Watson, Amgad Shebl, et al.
Pharmacoepidemiology and Drug Safety|June 19, 2003
Liver function testing in patients on HMG-CoA reductase inhibitorsSusan E Andrade, James G Donahue, K Arnold Chan, et al.
Current Medical Research and Opinion|October 7, 2004
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysisDouglas J Watson, Qinfen Yu, James A Bolognese, et al.
Open Access Rheumatology : Research and Reviews|July 29, 2013
A measure of treatment response: patient and physician satisfaction with traditional NSAIDs for osteoarthritis controlStephanie D Taylor, Sharlette V Everett, Thomas N Taylor, et al.
Pageof 4